Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Pizzuti L, et al. Among authors: gamucci t. Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7. Int J Cancer. 2020. PMID: 31330065 Free PMC article.
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F. Ceribelli A, et al. Among authors: gamucci t. Cancer. 2003 Jul 15;98(2):337-43. doi: 10.1002/cncr.11501. Cancer. 2003. PMID: 12872354 Free article. Clinical Trial.
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, De Marco S, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I, Cognetti F. Felici A, et al. Among authors: gamucci t. Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64. doi: 10.1007/s00280-005-0032-5. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16001173 Clinical Trial.
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R, Vitale S, Gamucci T, Mariani L. Gasparini G, et al. Among authors: gamucci t. Oncologist. 2005 Oct;10(9):710-7. doi: 10.1634/theoncologist.10-9-710. Oncologist. 2005. PMID: 16249351 Free article. Clinical Trial.
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S, Ferraresi V, Giannarelli D, Cognetti F, Zeuli M. Gelibter AJ, et al. Among authors: gamucci t. Curr Med Res Opin. 2007 Sep;23(9):2117-23. doi: 10.1185/030079907X226113. Curr Med Res Opin. 2007. PMID: 17651538 Clinical Trial.
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Pino MS, Gamucci T, Mansueto G, Trapasso T, Narducci F, Giampaolo MA, Fariello AM, Sperduti I, Ceribelli A, Cognetti F. Pino MS, et al. Among authors: gamucci t. Lung Cancer. 2008 Jun;60(3):381-6. doi: 10.1016/j.lungcan.2007.10.027. Epub 2007 Dec 19. Lung Cancer. 2008. PMID: 18068853 Clinical Trial.
152 results